论文部分内容阅读
目的:探讨非小细胞肺癌(NSCLC)患者外周血中髓样抑制细胞(MDSCs)的比例及其对CD8+T细胞的抑制作用。方法:密度梯度离心法分离30例NSCLC患者及15例健康对照者外周血单个核细胞(PBMC),流式抗体染色后经流式细胞仪检测MDSCs中CD11b、CD14和CD33的表达;磁珠分选法分离、纯化肿瘤患者外周血中的MDSCs及健康者外周血中的CD8+T细胞,1∶1共培养72小时,用ELISA法测定24、48、72小时细胞培养上清液的INF-γ水平。结果:30例进展期NSCLC患者外周血中MDSCs比例为(25.1±16.8)%,明显高于健康对照组(8.2±3.6)%,两者差异有统计学意义(P<0.001);未观察到MDSCs比例与患者年龄、性别、分期及病理类型有关(P>0.05);ELISA法显示:与CD8+T细胞单独培养组相比,MDSCs与CD8+T细胞组共培养24、48、72小时的培养上清IFN-γ水平由(201.3±14.57)ng/ml逐渐下降为(163.33±7.77)ng/ml、(132.0±6.9)ng/ml和(79.67±7.09)ng/ml,明显降低(P<0.05)。结论:进展期NSCLC患者外周血中MDSCs的比例较健康者明显升高,且对CD8+T细胞有抑制作用,MDSCs增多可能是NSCLC患者发生免疫抑制的重要原因之一。
Objective: To investigate the proportion of myeloid suppressor cells (MDSCs) in peripheral blood of non-small cell lung cancer (NSCLC) patients and its inhibitory effect on CD8 + T cells. Methods: Peripheral blood mononuclear cells (PBMCs) were isolated from 30 patients with NSCLC and 15 healthy controls by density gradient centrifugation. Flow cytometry was used to detect the expression of CD11b, CD14 and CD33 in MDSCs by flow cytometry. The CD8 + T cells in the peripheral blood of healthy patients and the MDSCs in the peripheral blood of healthy persons were purified and purified by the method of selection. The cells were co-cultured for 1 hour and 72 hours respectively. The expression of INF- γ level. Results: The proportion of MDSCs in peripheral blood of 30 patients with advanced NSCLC was (25.1 ± 16.8)%, significantly higher than that of healthy controls (8.2 ± 3.6)%, the difference was statistically significant (P <0.001); not observed The percentage of MDSCs was related to age, gender, stage and pathological type (P> 0.05). Compared with CD8 + T cells alone, MDSCs and CD8 + T cells co-cultured for 24, 48 and 72 hours The level of IFN-γ in culture supernatant decreased from (201.3 ± 14.57) ng / ml to (163.33 ± 7.77) ng / ml, (132.0 ± 6.9) ng / ml and (79.67 ± 7.09) ng / ml, <0.05). CONCLUSIONS: The proportion of MDSCs in peripheral blood of patients with advanced NSCLC is significantly higher than that of healthy people and inhibits CD8 + T cells. Increased MDSCs may be one of the important causes of immunosuppression in patients with NSCLC.